PL3486245T3 - 2-amino-n-(piperydyn-1-ylo-pirydyn-3-ylo) pirazolo[1,5alfa]pirymidyno-3-karboksyamid jako inhibitor kinazy atr - Google Patents

2-amino-n-(piperydyn-1-ylo-pirydyn-3-ylo) pirazolo[1,5alfa]pirymidyno-3-karboksyamid jako inhibitor kinazy atr

Info

Publication number
PL3486245T3
PL3486245T3 PL18212042T PL18212042T PL3486245T3 PL 3486245 T3 PL3486245 T3 PL 3486245T3 PL 18212042 T PL18212042 T PL 18212042T PL 18212042 T PL18212042 T PL 18212042T PL 3486245 T3 PL3486245 T3 PL 3486245T3
Authority
PL
Poland
Prior art keywords
carboxamid
5alpha
pyrazolo
piperidin
pyridin
Prior art date
Application number
PL18212042T
Other languages
English (en)
Polish (pl)
Inventor
Nadia AHMAD
Dean Boyall
Jean-Damien Charrier
Chris Davis
Rebecca Davis
Steven Durrant
Gorka ETXEBARRIA I JARDI
Damien Fraysse
Juan-Miguel Jimenez
David Kay
Ronald Knegtel
Donald MIDDELTON
Michael ODONNELL
Maninder PANESAR
Francoise Pierard
Joanne Pinder
David Shaw
Pierre-Henri Storck
John Studley
Heather Twin
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of PL3486245T3 publication Critical patent/PL3486245T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18212042T 2012-12-07 2013-12-06 2-amino-n-(piperydyn-1-ylo-pirydyn-3-ylo) pirazolo[1,5alfa]pirymidyno-3-karboksyamid jako inhibitor kinazy atr PL3486245T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261734726P 2012-12-07 2012-12-07
US201361787568P 2013-03-15 2013-03-15
US201361868132P 2013-08-21 2013-08-21
EP18159811.1A EP3418281B1 (en) 2012-12-07 2013-12-06 Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases
EP13811716.3A EP2941432B8 (en) 2012-12-07 2013-12-06 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5alpha]pyrimidine-3-carboxamide as inhibitor of atr kinase
EP18212042.8A EP3486245B1 (en) 2012-12-07 2013-12-06 2-amino-n-(piperidin-1-yl-pyridin-3-yl) pyrazolo[1,5alpha]pyrimidine-3-carboxamid as inhibitor of atr kinase
PCT/US2013/073457 WO2014089379A1 (en) 2012-12-07 2013-12-06 Compounds useful as inhibitors of atr kinase

Publications (1)

Publication Number Publication Date
PL3486245T3 true PL3486245T3 (pl) 2021-11-08

Family

ID=49877035

Family Applications (4)

Application Number Title Priority Date Filing Date
PL20198773.2T PL3808749T3 (pl) 2012-12-07 2013-12-06 Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
PL23153078.3T PL4190786T3 (pl) 2012-12-07 2013-12-06 Związki użyteczne jako inhibitory kinazy atr
PL18212042T PL3486245T3 (pl) 2012-12-07 2013-12-06 2-amino-n-(piperydyn-1-ylo-pirydyn-3-ylo) pirazolo[1,5alfa]pirymidyno-3-karboksyamid jako inhibitor kinazy atr
PL13811716T PL2941432T3 (pl) 2012-12-07 2013-12-06 2-Amino-6-fluoro-N-(5-fluoro-4-(4-(4-(oksetan-3-ylo)piperazyno-1-karbonylo)piperydyn-1-ylo)pirydyn-3-ylo)pirazoto[1,5alfa]pirymidino-3-karboksyamid jako inhibitor kinazy ATR

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL20198773.2T PL3808749T3 (pl) 2012-12-07 2013-12-06 Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
PL23153078.3T PL4190786T3 (pl) 2012-12-07 2013-12-06 Związki użyteczne jako inhibitory kinazy atr

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13811716T PL2941432T3 (pl) 2012-12-07 2013-12-06 2-Amino-6-fluoro-N-(5-fluoro-4-(4-(4-(oksetan-3-ylo)piperazyno-1-karbonylo)piperydyn-1-ylo)pirydyn-3-ylo)pirazoto[1,5alfa]pirymidino-3-karboksyamid jako inhibitor kinazy ATR

Country Status (31)

Country Link
US (9) US9340546B2 (enExample)
EP (6) EP3418281B1 (enExample)
JP (2) JP6401709B2 (enExample)
KR (1) KR102213986B1 (enExample)
CN (4) CN107501274B (enExample)
AU (2) AU2013355124B2 (enExample)
BR (1) BR112015012454B1 (enExample)
CA (1) CA2892608C (enExample)
CY (4) CY1120232T1 (enExample)
DK (5) DK3808749T3 (enExample)
ES (5) ES3030549T3 (enExample)
FI (2) FI3808749T3 (enExample)
HK (1) HK1209746A1 (enExample)
HR (5) HRP20180859T1 (enExample)
HU (5) HUE071468T2 (enExample)
IL (2) IL239218A0 (enExample)
LT (5) LT4190786T (enExample)
ME (1) ME03036B (enExample)
MX (1) MX368042B (enExample)
NZ (2) NZ731337A (enExample)
PL (4) PL3808749T3 (enExample)
PT (5) PT4190786T (enExample)
RS (5) RS61319B1 (enExample)
RU (1) RU2689996C2 (enExample)
SG (2) SG11201504467YA (enExample)
SI (5) SI4190786T1 (enExample)
SM (4) SMT202100425T1 (enExample)
TR (1) TR201807740T4 (enExample)
TW (1) TWI618706B (enExample)
WO (1) WO2014089379A1 (enExample)
ZA (2) ZA201503871B (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3354650T1 (sl) 2008-12-19 2022-06-30 Vertex Pharmaceuticals Incorporated Spojine, uporabne kot zaviralci ATR kinaze
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP6212045B2 (ja) 2011-09-30 2017-10-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス
BR112014007690B1 (pt) 2011-09-30 2022-10-04 Vertex Pharmaceuticals Incorporated Usos de inibidores de atr no tratamento de câncer pancreático e câncer de pulmão de células não pequenas
DK2833973T3 (en) 2012-04-05 2018-01-02 Vertex Pharma Compounds useful as ATR kinase inhibitors and combination therapies thereof
EP3418281B1 (en) 2012-12-07 2020-09-30 Vertex Pharmaceuticals Inc. Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
UA121098C2 (uk) 2013-01-15 2020-04-10 Інсайт Холдинґс Корпорейшн Тіазолкарбоксаміди і піридинкарбоксаміди, які використовуються як інгібітори рім-кінази
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2016512239A (ja) 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
WO2015027124A1 (en) * 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
EP3077397B1 (en) * 2013-12-06 2019-09-18 Vertex Pharmaceuticals Inc. 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
CA2950780C (en) * 2014-06-17 2023-05-16 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
WO2016010897A1 (en) * 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
CN107108581B (zh) * 2014-08-21 2020-06-23 百时美施贵宝公司 作为强效rock抑制剂的回接苯甲酰胺衍生物
DK3215511T3 (da) 2014-11-06 2024-05-13 Bial R&D Invest S A Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser
WO2016073891A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
WO2017059357A1 (en) * 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
JP7560026B2 (ja) * 2016-01-08 2024-10-02 ザ インスティチュート オブ キャンサー リサーチ，ロイヤル キャンサー ホスピタル 癌を治療する方法における使用のための毛細血管拡張性運動失調症の変異したＲａｄ３関連タンパク質キナーゼ（ＡＴＲ）の阻害剤
IL260487B2 (en) 2016-01-11 2024-11-01 Merrimack Pharmaceuticals Inc Inhibition of ataxia capillary dilation and related protein- (ATR) RAD3
BR112018016133A2 (pt) * 2016-02-16 2019-01-02 Massachusetts Inst Technology aglutinantes de max como moduladores de myc e usos dos mesmos
EP3440083A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. IMIDAZO [1,5-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
JP7038063B2 (ja) 2016-04-06 2022-03-17 リソソーマル・セラピューティクス・インコーポレイテッド ピラゾロ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
AU2017261291C1 (en) 2016-05-05 2022-05-26 Bial - R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
EP3535273A1 (en) * 2016-11-02 2019-09-11 H. Hoffnabb-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
WO2018153972A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and antiandrogens
WO2018153969A1 (en) 2017-02-24 2018-08-30 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with radium-223 salt
CN106946890A (zh) * 2017-04-26 2017-07-14 中国药科大学 吡啶类irak4抑制剂、其制备方法及应用
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
EP3630116B1 (en) 2017-05-26 2024-05-01 The Board Of Regents Of The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
SI3651768T1 (sl) 2017-07-13 2024-05-31 Chempartner Corporation Heterociklični inhibitorji atr kinaze
WO2019023468A1 (en) 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
CA3071760A1 (en) 2017-08-04 2019-02-07 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors
JP7290627B2 (ja) 2017-08-17 2023-06-13 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN107935918A (zh) * 2017-11-15 2018-04-20 山东潍坊润丰化工股份有限公司 一种百草枯的制备方法
US11612666B2 (en) * 2017-11-30 2023-03-28 Seagen Inc. Process for the preparation of drug linker compounds
CA3084863A1 (en) 2017-12-08 2019-06-13 Bayer Aktiengesellschaft Predictive markers for atr kinase inhibitors
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
US20210196751A1 (en) * 2017-12-29 2021-07-01 Vertex Pharmaceuticals Incorporated Methods of cancer treatment using an atr inhibitor
JP7341156B2 (ja) 2018-03-16 2023-09-08 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
CA3114024A1 (en) 2018-09-26 2020-04-02 Merck Patent Gmbh Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
CN113164447A (zh) 2018-10-15 2021-07-23 默克专利股份公司 利用dna烷化剂和atr抑制剂的组合疗法
EP3866805A1 (en) 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CN112142744A (zh) 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
WO2021178832A2 (en) * 2020-03-06 2021-09-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Dna damage repair genes in cancer
WO2021187605A1 (ja) * 2020-03-19 2021-09-23 田辺三菱製薬株式会社 含窒素複素環αシアノカルボニル化合物
CA3183649A1 (en) * 2020-06-18 2021-12-23 Merck Patent Gmbh Compounds for the treatment of viral infections
CN115867552B (zh) * 2020-07-02 2024-12-13 江苏恒瑞医药股份有限公司 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
EP4166556A4 (en) * 2020-07-13 2024-06-26 Beijing Tide Pharmaceutical Co., Ltd. PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR
CA3225945A1 (en) * 2021-07-16 2023-01-19 Tuan Trang Sulfamoyl benzene derivatives and uses thereof
EP4392418A4 (en) * 2021-08-24 2025-06-18 The Johns Hopkins University Compositions and methods for treating proteotoxicity-associated diseases
CN116283960A (zh) 2021-12-21 2023-06-23 上海安诺达生物科技有限公司 取代的稠杂环化合物及其制备方法与应用
WO2023116865A1 (zh) * 2021-12-23 2023-06-29 优领医药科技（上海）有限公司 含吡唑类衍生物、其药学上可接受的盐及其制备方法和应用
CN115322143B (zh) * 2022-07-21 2023-07-14 安徽德诺医药股份有限公司 一种4-哌啶甲酸叔丁酯盐酸盐的制备方法
WO2025029842A2 (en) 2023-08-01 2025-02-06 Principia Biopharma Inc. Process of making 2-[(3r)-2-[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4- methyl-4[4-(oxetan-3-yl)piperazin-l-yl]-pent-2-enenitrile and solvate forms thereof

Family Cites Families (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309430A (en) 1980-06-27 1982-01-05 Merck & Co., Inc. Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
JP2597917B2 (ja) 1990-04-26 1997-04-09 富士写真フイルム株式会社 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料
BR9608100A (pt) 1995-05-09 1999-02-23 Basf Ag Pirazolo[1,5a] pirimidina processos para a sua preparação e para o controle e fungos nocivos e pragas composição e utilização dos compostos
CA2253910A1 (en) 1996-05-11 1997-11-20 King's College London Pyrazines
DK0915880T3 (da) 1996-07-24 2008-02-11 Bristol Myers Squibb Pharma Co Azolotriaziner og pyrimidiner
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
JPH10218881A (ja) 1997-02-03 1998-08-18 Pola Chem Ind Inc 新規なピロロピラゾロピリミジン誘導体
GB2323861B (en) 1997-02-05 2001-06-20 Sector Exhibiting Systems Artificial wall structure
JP2002241379A (ja) 1997-03-21 2002-08-28 Dainippon Pharmaceut Co Ltd ３−オキサジアゾリルキノキサリン誘導体
EP0984692A4 (en) 1997-05-30 2001-02-21 Merck & Co Inc ANGIOGENESIS INHIBITORS
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
TW548275B (en) 1998-07-16 2003-08-21 Shionogi & Co A pyrimidine derivative having antiturnor activity
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP2001302666A (ja) 1999-09-21 2001-10-31 Nissan Chem Ind Ltd アゾール縮合ヘテロ環アニライド化合物及び除草剤
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
AU782858B2 (en) 1999-12-17 2005-09-01 Novartis Vaccines And Diagnostics, Inc. Pyrazine based inhibitors of glycogen synthase kinase 3
AU2001264932A1 (en) 2000-05-26 2001-12-11 Neurogen Corporation Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US6420637B1 (en) 2001-01-29 2002-07-16 Asgrow Seed Company L.L.C. Plants and seeds of corn variety I389972
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
DE60229059D1 (de) 2001-05-08 2008-11-06 Univ Yale Proteomimetische verbindungen und verfahren
US20030114467A1 (en) 2001-06-21 2003-06-19 Shakespeare William C. Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
ATE541847T1 (de) 2001-11-01 2012-02-15 Icagen Inc Pyrazolopyrimidine als natriumkanalblocker
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
EP1446387B1 (en) 2001-11-21 2009-11-04 Pharmacia & Upjohn Company LLC Substituted aryl 1,4-pyrazine derivatives
MXPA04007697A (es) 2002-02-06 2004-11-10 Vertex Pharma Compuestos de heteroarilo utiles como inhibidores de gsk-3.
US7205304B2 (en) 2002-03-13 2007-04-17 Janssen Pharmaceutica N.V. Sulfonyl-Derivatives as novel inhibitors of histone deacetylase
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
AU2003227437A1 (en) * 2002-04-23 2003-11-10 Shionogi And Co., Ltd. PYRAZOLO(1,5-a)PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
KR20050004214A (ko) 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
DE60319820T2 (de) 2002-06-04 2009-03-26 Schering Corp. Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2497450C (en) 2002-09-04 2011-05-31 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7601724B2 (en) 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
CN1310918C (zh) 2002-09-04 2007-04-18 先灵公司 作为细胞周期蛋白依赖激酶抑制剂的吡唑并嘧啶
ES2283868T3 (es) 2002-09-04 2007-11-01 Schering Corporation Compuestos pirazol(1,5-a) pirimidina como inhibidores de quinasa dependiente de ciclina.
ATE469903T1 (de) 2002-09-04 2010-06-15 Schering Corp Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
AU2003282679A1 (en) 2002-10-04 2004-05-04 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
AU2003299651A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
CN103265477B (zh) 2003-02-26 2017-01-11 苏根公司 作为蛋白激酶抑制剂的氨基杂芳基化合物
BRPI0407834A (pt) 2003-02-28 2006-02-14 Teijin Pharma Ltd composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
BRPI0408251A (pt) 2003-03-11 2006-03-01 Pfizer Prod Inc compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
US7459454B2 (en) 2003-03-21 2008-12-02 Smithkline Beecham Corporation Aminopyrazine derivatives and compositions
CN101468965A (zh) 2003-03-24 2009-07-01 默克公司 联芳基取代的6元杂环钠通道阻滞剂
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2004103279A2 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
BRPI0414533A (pt) 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
US7807696B2 (en) 2003-10-07 2010-10-05 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
ES2369835T3 (es) 2003-11-19 2011-12-07 Array Biopharma, Inc. Inhibidores bicíclicos de mek y métodos de síntesis de los mismos.
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
EP1715867A4 (en) 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
JP2007523939A (ja) 2004-02-25 2007-08-23 ビーエーエスエフ　アクチェンゲゼルシャフト アゾロピリミジン化合物及び寄生性菌類を駆除するためのその使用
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
US20080153869A1 (en) 2004-06-14 2008-06-26 Bressi Jerome C Kinase Inhibitors
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
EP2239262A3 (en) 2004-07-27 2011-10-19 SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
AU2005304784B2 (en) 2004-11-04 2011-03-24 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
EP1828144A2 (en) 2004-11-12 2007-09-05 OSI Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
CA2587926A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
WO2006071548A2 (en) 2004-12-27 2006-07-06 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20060156482A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
EP1848710B1 (en) 2005-02-16 2013-10-16 Merck Sharp & Dohme Corp. Heterocyclic substituted piperazines with cxcr3 antagonist activity
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
EP1874769B1 (de) 2005-04-25 2011-09-14 Merck Patent GmbH Neuartige aza-heterozyklen als kinase-inhibitoren
US20070155737A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
EA013525B1 (ru) 2005-05-20 2010-06-30 Алантос-Фармасьютикалз Холдинг, Инк. Гетеробициклические ингибиторы металлопротеазы и их применение
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
WO2007015632A1 (en) 2005-08-04 2007-02-08 Cgk Co., Ltd. Atm and atr inhibitor
TW200745123A (en) 2005-10-06 2007-12-16 Schering Corp Pyrazolopyrimidines as protein kinase inhibitors
TWI421078B (zh) 2005-10-06 2014-01-01 Merck Sharp & Dohme 關卡激酶抑制劑及其用途
TWI333953B (en) 2005-10-06 2010-12-01 Schering Corp Pyrazolopyrimidines as protein kinase inhibitors
CA2624500A1 (en) * 2005-10-06 2007-04-19 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US8372851B2 (en) 2005-10-21 2013-02-12 Exelixis, Inc. Pyrazolo pyrimidines as casein kinase II (CK2) modulators
AU2006305104B2 (en) 2005-10-21 2009-10-22 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
TW200736260A (en) 2005-11-10 2007-10-01 Smithkline Beecham Corp Inhibitors of Akt activity
AU2006319247B2 (en) 2005-12-01 2010-03-11 F. Hoffmann-La Roche Ag Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors
WO2007066805A1 (ja) 2005-12-09 2007-06-14 Meiji Seika Kaisha, Ltd. リンコマイシン誘導体およびこれを有効成分とする抗菌剤
BRPI0620463A2 (pt) 2005-12-22 2011-11-16 Alcon Res Ltd composição farmacêutica oftálmica, compostos, e seus usos
ITMI20060311A1 (it) 2006-02-21 2007-08-22 Btsr Int Spa Dispositivo perfezionato di alimentazione di filo o filatio ad una macchina tessile e metodo per attuare tale alimentazione
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
JP2009533327A (ja) 2006-03-22 2009-09-17 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患を処置するためのｃ−ＭＥＴキナーゼ阻害剤
WO2007126841A2 (en) 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
AR060336A1 (es) 2006-03-31 2008-06-11 Schering Corp Derivados de indazolilpirazinilo inhibidores de proteinquinasas, composiciones farmaceuticas que los contienen y usos como agentes anticancer,entre otros.
PE20080071A1 (es) 2006-05-22 2008-02-11 Schering Corp PIRAZOLO[1,5-a]PIRIMIDINAS
EP2044051B1 (en) 2006-06-22 2010-01-27 BIOVITRUM AB (publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
US9216963B2 (en) 2006-06-22 2015-12-22 Medibeacon Inc. Pyrazine derivatives with extended conjugation and methods of using the same in optical applications
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
DE602007013441D1 (de) 2006-09-29 2011-05-05 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
GB0619342D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
MX2009003222A (es) 2006-10-04 2009-04-06 Hoffmann La Roche Derivados de 3-piridinocarboxamida y 2-pirazinocarboxamida como agentes elevadores de colesterol de lipoproteina de alta densidad.
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
EP2081928B1 (en) 2006-11-10 2014-02-26 Bristol-Myers Squibb Company Pyrrolo-pyridine kinase inhibitors
AU2007321924A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
WO2008071456A2 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft 3-h-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
CA2679659C (en) 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
AU2008235089B8 (en) 2007-04-10 2014-04-10 Bayer Intellectual Property Gmbh Insecticidal aryl isoxazoline derivatives
US7592342B2 (en) 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2014661A1 (de) 2007-06-13 2009-01-14 Bayer CropScience AG Heterocyclisch substituierte Heterocyclyl-carbonsäurederivate
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
EP2157090A4 (en) 2007-06-21 2011-09-07 Taisho Pharmaceutical Co Ltd PYRAZINAMIDE COMPOUND
WO2009002964A1 (en) 2007-06-26 2008-12-31 Lexicon Pharmaceuticals, Inc. Methods of treating serotonin-mediated diseases and disorders
WO2009006580A1 (en) 2007-07-05 2009-01-08 Cv Therapeutics, Inc. Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
US20100292236A1 (en) 2007-07-19 2010-11-18 H. Lundbeck A/S 5-Membered Heterocyclic Amides And Related Compounds
MY150032A (en) 2007-07-19 2013-11-29 Merck Sharp & Dohme Heterocyclic amide compounds as protein kinase inhibitors
KR20100038119A (ko) 2007-08-01 2010-04-12 화이자 인코포레이티드 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
WO2009037247A1 (en) 2007-09-17 2009-03-26 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
MX2010004491A (es) 2007-10-25 2010-06-21 Astrazeneca Ab Derivados de piridina y pirazina utiles en el tratamiento de trastornos proliferativos celulares.
EP2225247A1 (en) 2007-11-28 2010-09-08 Schering Corporation 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
WO2009075790A1 (en) 2007-12-07 2009-06-18 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors for intra-articular application
KR20100108390A (ko) 2007-12-19 2010-10-06 버텍스 파마슈티칼스 인코포레이티드 ＪＡＫ２ 억제제로서 유용한 피라졸로［１，５－ａ］피리미딘
CN104926815B (zh) 2008-01-04 2017-11-03 英特利凯恩有限责任公司 某些化学实体、组合物和方法
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
CN101945877B (zh) 2008-02-25 2013-07-03 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
MX2010008198A (es) 2008-02-25 2010-08-23 Hoffmann La Roche Inhibidores de cinasa de pirrolopirazina.
JP5529049B2 (ja) 2008-02-25 2014-06-25 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼ阻害剤
BRPI0907928A2 (pt) 2008-02-25 2015-07-28 Hoffmann La Roche Inibidores de pirrolopirazina quinase.
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
JP2011515401A (ja) 2008-03-20 2011-05-19 アムジエン・インコーポレーテツド オーロラキナーゼモジュレーターおよび使用方法
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
WO2010006086A2 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
GB0814364D0 (en) 2008-08-05 2008-09-10 Eisai London Res Lab Ltd Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase
WO2010017047A1 (en) 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
WO2010034738A2 (en) 2008-09-24 2010-04-01 Basf Se Pyrazole compounds for controlling invertebrate pests
CN102317277A (zh) 2008-10-21 2012-01-11 沃泰克斯药物股份有限公司 C-met蛋白激酶抑制剂
CA2740792C (en) 2008-10-31 2016-06-21 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
EP2370424A1 (en) 2008-11-10 2011-10-05 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
EP3037421A3 (en) 2008-11-25 2016-11-30 University Of Rochester Mlk inhibitors and methods of use
BRPI0922937A2 (pt) 2008-12-05 2019-09-24 Hoffmann La Roche inibidores de pirrolopirazinil uréia quinase
SI3354650T1 (sl) 2008-12-19 2022-06-30 Vertex Pharmaceuticals Incorporated Spojine, uporabne kot zaviralci ATR kinaze
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010087430A1 (ja) 2009-01-30 2010-08-05 富山化学工業株式会社 Ｎ－アシルアントラニル酸誘導体またはその塩
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
AU2010214101A1 (en) 2009-02-11 2011-09-01 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
CN101537007A (zh) 2009-03-18 2009-09-23 中国医学科学院血液病医院（血液学研究所） N-(噻吩-2)吡唑并[1,5-a]嘧啶-3-甲酰胺类化合物在制备抗恶性肿瘤药物方面的应用
US20120065247A1 (en) 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2454262B1 (en) 2009-07-15 2014-05-14 Abbott Laboratories Pyrrolopyrazine inhibitors of kinases
AU2010284254B2 (en) 2009-08-17 2015-09-17 Intellikine, Llc Heterocyclic compounds and uses thereof
EP2470183B1 (en) 2009-08-26 2015-09-16 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
PL2509602T3 (pl) 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
GB2481563B (en) 2009-12-22 2017-07-19 Intel Corp Method and apparatus to provide secure application execution
CA2793086C (en) 2010-03-18 2018-08-21 Institut Pasteur Korea Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
WO2011121096A1 (en) 2010-03-31 2011-10-06 Dkfz Deutsches Krebsforschungszentrum PYRAZOL[1,5-a]PYRIMIDINE DERIVATIVES AS WNT PATHWAY ANTAGONISTS
WO2011124998A1 (en) 2010-04-08 2011-10-13 Pfizer Inc. Substituted 3,5- di phenyl - isoxazoline derivatives as insecticides and acaricides
US20130030237A1 (en) 2010-04-15 2013-01-31 Charles Theuer Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
AU2011253025A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2568984A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2013529200A (ja) 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
EP2569287B1 (en) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
AU2011253021A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated 2 -aminopyridine derivatives useful as inhibitors of ATR kinase
WO2011143419A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
CN103003281A (zh) 2010-05-20 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为JAK和SYK抑制剂的吡咯并[2，3-b]吡嗪-7-甲酰胺衍生物和它们的用途
TWI496785B (zh) 2010-05-20 2015-08-21 Hoffmann La Roche 吡咯并吡激酶抑制劑
AU2011270807A1 (en) 2010-06-23 2013-01-31 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of ATR kinase
US8486938B2 (en) 2010-06-24 2013-07-16 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines for antiviral treatment
CN102311396B (zh) 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
MX358682B (es) 2010-07-13 2018-08-31 Hoffmann La Roche Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
EP2407478A1 (en) 2010-07-14 2012-01-18 GENETADI Biotech, S.L. New cyclotetrapeptides with pro-angiogenic properties
WO2012022045A1 (en) 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012067822A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
CA2817968C (en) 2010-11-16 2019-03-12 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
US9353117B2 (en) 2010-12-08 2016-05-31 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
MX2013011450A (es) * 2011-04-05 2014-02-03 Vertex Pharma Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
CN103619845B (zh) 2011-04-21 2016-08-17 拜耳知识产权有限责任公司 氟烷基取代的吡唑并吡啶及其用途
JP2014513728A (ja) 2011-05-17 2014-06-05 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤としてのアザインドール誘導体
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
EP2723384B1 (en) 2011-06-22 2018-08-29 The General Hospital Corporation Treatment of proteinopathies
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
CN103857396A (zh) 2011-07-13 2014-06-11 药品循环公司 布鲁顿酪氨酸激酶抑制剂
WO2013052263A2 (en) 2011-09-16 2013-04-11 Microbiotix, Inc. Antifungal compounds
BR112014007690B1 (pt) 2011-09-30 2022-10-04 Vertex Pharmaceuticals Incorporated Usos de inibidores de atr no tratamento de câncer pancreático e câncer de pulmão de células não pequenas
EP2751088B1 (en) 2011-09-30 2016-04-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP6212045B2 (ja) 2011-09-30 2017-10-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス
MX2014003796A (es) 2011-09-30 2015-01-16 Vertex Pharma Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
CN104394869A (zh) 2011-10-20 2015-03-04 葛兰素史密斯克莱有限责任公司 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9193725B2 (en) 2012-03-14 2015-11-24 Bristol-Meyers Squibb Company Cyclic hydrazine derivatives as HIV attachment inhibitors
SG10201701101YA (en) 2012-04-02 2017-04-27 Cytokinetics Inc Methods for improving diaphragm function
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
DK2833973T3 (en) 2012-04-05 2018-01-02 Vertex Pharma Compounds useful as ATR kinase inhibitors and combination therapies thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
CA2870837C (en) 2012-05-15 2022-05-10 Cancer Research Technology Limited 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
WO2013174930A2 (en) 2012-05-23 2013-11-28 Savira Pharmaceuticals Gmbh 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
BR112014029006A2 (pt) 2012-05-23 2017-06-27 European Molecular Biology Laboratory derivados de 7-oxo-4,7-di-hidro-pirazolo[1,5-a]pirimidina que são úteis no tratamento, melhora ou prevenção de uma doença viral
WO2014011911A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
MX2015001478A (es) 2012-08-06 2015-08-12 Savira Pharmaceuticals Gmbh Derivados de acido dihidroxipirimidina, carbonico y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
WO2014025852A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic alkene derivatives as hiv attachment inhibitors
ES2616492T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de piperidina amida como inhibidores de la fijación del VIH
WO2014025850A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic amidine derivatives as hiv attachment inhibitors
RU2015109064A (ru) 2012-08-17 2016-10-10 Байер Кропсайенс Аг Амиды азаиндолкарбоновых и азаиндолтиокарбоновых кислот в качестве инсектицитов и акарицидов
CA2873295A1 (en) 2012-08-24 2014-02-27 F. Hoffmann-La Roche Ag New bicyclicpyridine derivatives
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
EP2909212B1 (en) 2012-09-07 2017-02-22 Takeda Pharmaceutical Company Limited Substituted 1,4-dihydropyrazolo[4,3-b]indoles
WO2014042433A2 (en) 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP2897618B1 (en) 2012-09-24 2021-11-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
CA2900335C (en) 2012-10-22 2021-10-26 City Of Hope Synthetic analogs of epipolythiodioxopiperazines and uses thereof
ES2628529T3 (es) 2012-10-24 2017-08-03 Tintes de cianina-azaindolina sustituidos con hidroxamato, y bioconjugados de los mismos
EP3418281B1 (en) 2012-12-07 2020-09-30 Vertex Pharmaceuticals Inc. Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases
JP2016512239A (ja) 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP3077397B1 (en) 2013-12-06 2019-09-18 Vertex Pharmaceuticals Inc. 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
US20150158868A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
CA2950780C (en) 2014-06-17 2023-05-16 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors

Also Published As

Publication number Publication date
RU2689996C2 (ru) 2019-05-30
EP4190786A1 (en) 2023-06-07
US20250223292A1 (en) 2025-07-10
EP4190786B1 (en) 2025-02-26
DK3486245T3 (da) 2021-07-19
RS62174B1 (sr) 2021-08-31
PL2941432T3 (pl) 2018-09-28
US9718827B2 (en) 2017-08-01
US9340546B2 (en) 2016-05-17
HK1217190A1 (en) 2016-12-30
RS66820B1 (sr) 2025-06-30
DK4190786T3 (da) 2025-06-02
ES2946360T3 (es) 2023-07-17
JP2018087213A (ja) 2018-06-07
SG10201606373XA (en) 2016-09-29
US10787452B2 (en) 2020-09-29
HK1209746A1 (en) 2016-04-08
IL263262A (en) 2018-12-31
CN107501275B (zh) 2019-11-22
HRP20202058T1 (hr) 2021-02-19
ZA201503871B (en) 2016-11-30
WO2014089379A1 (en) 2014-06-12
ES2669423T3 (es) 2018-05-25
CN107501274A (zh) 2017-12-22
TR201807740T4 (tr) 2018-06-21
HUE055618T2 (hu) 2021-12-28
PT3486245T (pt) 2021-07-30
AU2013355124B2 (en) 2018-03-22
PT3808749T (pt) 2023-06-07
FI3808749T3 (fi) 2023-05-31
US20160347754A1 (en) 2016-12-01
SMT202300157T1 (it) 2023-07-20
BR112015012454A2 (pt) 2017-07-11
BR112015012454B1 (pt) 2022-07-05
SG11201504467YA (en) 2015-07-30
JP6574859B2 (ja) 2019-09-11
EP2941432A1 (en) 2015-11-11
SMT202100425T1 (it) 2021-09-14
DK3418281T3 (da) 2020-12-07
ZA201605990B (en) 2019-12-18
US11117900B2 (en) 2021-09-14
RU2015127079A (ru) 2017-01-10
US20180072735A1 (en) 2018-03-15
SMT201800279T1 (it) 2018-07-17
TW201434839A (zh) 2014-09-16
TWI618706B (zh) 2018-03-21
EP3808749A1 (en) 2021-04-21
LT3418281T (lt) 2021-01-11
HRP20250581T1 (hr) 2025-07-04
LT3486245T (lt) 2021-08-25
ES2842876T3 (es) 2021-07-15
SI3418281T1 (sl) 2021-02-26
MX2015007101A (es) 2015-09-29
SI3808749T1 (sl) 2023-07-31
FI4190786T3 (fi) 2025-05-23
HUE037371T2 (hu) 2018-08-28
HUE071468T2 (hu) 2025-08-28
HRP20180859T1 (hr) 2018-07-13
AU2013355124A1 (en) 2015-06-18
PL3808749T3 (pl) 2023-07-10
US20140249157A1 (en) 2014-09-04
PT2941432T (pt) 2018-06-01
DK3808749T3 (da) 2023-06-06
SI4190786T1 (sl) 2025-07-31
US20180155346A1 (en) 2018-06-07
CA2892608A1 (en) 2014-06-12
CY1126044T1 (el) 2023-11-15
LT4190786T (lt) 2025-06-10
LT2941432T (lt) 2018-06-11
HRP20230476T1 (hr) 2023-07-21
SI3486245T1 (sl) 2021-09-30
CN107501274B (zh) 2019-11-22
ME03036B (me) 2018-10-20
JP2016501244A (ja) 2016-01-18
EP3486245A1 (en) 2019-05-22
ES3030549T3 (en) 2025-06-30
US10392391B2 (en) 2019-08-27
SMT202000713T1 (it) 2021-03-15
IL263262B (en) 2019-07-31
NZ630457A (en) 2017-05-26
CA2892608C (en) 2021-10-19
US11370798B2 (en) 2022-06-28
SI2941432T1 (en) 2018-07-31
IL239218A0 (en) 2015-07-30
US20230271963A1 (en) 2023-08-31
ES2884030T3 (es) 2021-12-10
CN104903325B (zh) 2017-10-20
JP6401709B2 (ja) 2018-10-10
WO2014089379A9 (en) 2015-01-15
US12187731B2 (en) 2025-01-07
AU2018204431B2 (en) 2020-04-02
BR112015012454A8 (pt) 2019-10-01
EP2941432B8 (en) 2018-06-27
PT4190786T (pt) 2025-05-29
KR20150091171A (ko) 2015-08-07
KR102213986B1 (ko) 2021-02-09
HRP20211034T1 (hr) 2021-12-10
RS57210B1 (sr) 2018-07-31
DK2941432T3 (en) 2018-06-14
NZ731337A (en) 2019-02-22
US20210047333A1 (en) 2021-02-18
EP4534538A2 (en) 2025-04-09
EP3808749B1 (en) 2023-03-08
CN107629059A (zh) 2018-01-26
CN107501275A (zh) 2017-12-22
EP3418281A1 (en) 2018-12-26
HUE061909T2 (hu) 2023-08-28
EP2941432B1 (en) 2018-03-07
HUE052808T2 (hu) 2021-05-28
EP3486245B1 (en) 2021-04-28
PL4190786T3 (pl) 2025-06-23
CY1124291T1 (el) 2022-07-22
RS64234B1 (sr) 2023-06-30
MX368042B (es) 2019-09-17
US9650381B2 (en) 2017-05-16
AU2018204431A1 (en) 2018-07-05
EP3418281B1 (en) 2020-09-30
RS61319B1 (sr) 2021-02-26
CN107629059B (zh) 2020-07-28
CY1123702T1 (el) 2022-03-24
US20140163000A1 (en) 2014-06-12
LT3808749T (lt) 2023-06-12
PT3418281T (pt) 2020-12-30
CN104903325A (zh) 2015-09-09
CY1120232T1 (el) 2019-07-10
US20200140441A1 (en) 2020-05-07
EP4534538A3 (en) 2025-06-11

Similar Documents

Publication Publication Date Title
PT3486245T (pt) 2-amino-n-(piperidin-1-il-piridin-3- il)pirazolo[1,5alfa]pirimidina-3-carboxamida como inibidor da quinase atr
IL261282A (en) Furinone compounds as kinase inhibitors
IL238728A0 (en) Pyrrolopyrimidine compounds as kinase inhibitors
ZA201307839B (en) Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
ZA201406777B (en) 3,5-diaminopyrazole kinase inhibitors
ZA201403651B (en) Pyrazine kinase inhibitors
AP2015008532A0 (en) Syk kinase inhibitors as treatment for malaria